Cyclin-Dependent Kinase Inhibitor p15
"Cyclin-Dependent Kinase Inhibitor p15" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An INK4 cyclin-dependent kinase inhibitor containing four ANKYRIN-LIKE REPEATS. INK4B is often inactivated by deletions, mutations, or hypermethylation in HEMATOLOGIC NEOPLASMS.
| Descriptor ID |
D050762
|
| MeSH Number(s) |
D12.644.360.225.100 D12.776.167.187.100 D12.776.476.225.100 D12.776.624.776.355.100
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p15- Cyclin-Dependent Kinase Inhibitor p15
- Cyclin Dependent Kinase Inhibitor p15
- INK4B Protein
- CDKN2B Protein
- INK4b Cyclin-Dependent Kinase Inhibitor
- INK4b Cyclin Dependent Kinase Inhibitor
- p15INK4B Protein
- p15 CDK4 Inhibitor
- CDK4 Inhibitor, p15
- Cyclin-Dependent Kinase Inhibitor 2B
- Cyclin Dependent Kinase Inhibitor 2B
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p15".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p15".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p15" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p15" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2006 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p15" by people in Profiles.
-
Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas. Neuro Oncol. 2024 06 03; 26(6):1042-1051.
-
Genome-wide analysis of acute leukemia and clonally related histiocytic sarcoma in a series of three pediatric patients. Pediatr Blood Cancer. 2020 02; 67(2):e28074.
-
Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nat Commun. 2019 11 07; 10(1):5076.
-
An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion. Acta Neuropathol Commun. 2019 07 09; 7(1):110.
-
PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia. 2019 08; 33(8):1895-1909.
-
Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners. J Biol Chem. 2019 03 29; 294(13):4898-4910.
-
Undifferentiated Sarcomas in Children Harbor Clinically Relevant Oncogenic Fusions and Gene Copy-Number Alterations: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 08 15; 24(16):3888-3897.
-
Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nat Commun. 2015 Jun 24; 6:7553.
-
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro Oncol. 2014 Oct; 16(10):1333-40.
-
Pleiotropic associations of risk variants identified for other cancers with lung cancer risk: the PAGE and TRICL consortia. J Natl Cancer Inst. 2014 Apr; 106(4):dju061.